CellEDIT - CRISPR-Edited A549 Cell Line

Let us support you with a custom, high-quality engineered A549 cell line.

We'll handle the CRISPR engineering of your A549 cells, so you focus on your research. 


A549 cells are lung carcinoma epithelial cells that are widely used in cancer research and drug discovery. They are the most used human non-small cell lung cancer cell line. These hypotriploid alveolar basal epithelial cells were first derived in 1972 from the cultured pulmonary carcinoma tissue of a 58-year-old Caucasian male.

A549 Cell Line Information

Organism

Human

Tissue Type

Lung

Cell Type

Epithelial

Disease

Carcinoma

Karyotype

Hypotriploid

Donor Information

Age

58

Gender

Male

Ethnicity

Caucasian

A549 Cell Line Applications


 Cancer Research: A549 cells are extensively used to study the biology of non-small cell lung cancer, including tumor growth, metastasis, and the molecular mechanisms underlying cancer progression.

 

 Drug Screening & Development: These cells serve as a standard model for testing the efficacy and toxicity of new anticancer drugs, aiding in the identification and optimization of potential therapeutic compounds.

 

 Toxicology Studies: A549 cells are used to assess the cytotoxic effects of various chemicals, environmental pollutants, and potential therapeutic agents, providing insights into their safety and mechanism of action.

 

 Virology Research: Researchers utilize A549 cells to study viral infections, including the mechanisms of viral entry, replication, and host cell response, as well as to develop and test antiviral drugs.


 Respiratory Disease Research: These cells are employed to investigate respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, helping to understand disease mechanisms and develop new treatments.

 

Related Case Studies


Leverage CellEDIT's expertise to boost your research endeavor. With the CellEDIT workflow and within 10 weeks, we can support you with custom and monoclonal knockout A549 cell lines suited for your project needs.

CellEDIT Engineered A549 Cell Line - Cytosurge
Efficient on 
Hard-to-transfect cells
CellEDIT Engineered A549 Cell Line - Cytosurge
Vector-free 
direct intra-nuclear delivery
CellEDIT Engineered A549 Cell Line - Cytosurge
Minimized Off-Target

Immortalized Cells

Find out how 
the CellEDIT workflow enabled the generation of 5 monoclonal HPRT  knockout C2C12 cell lines through direct intra-nuclear injection of only 51 cells.

Hard-to-Transfect Cells

Discover how 
the CellEDIT workflow facilitated the production of 3 monoclonal HPRT1 knockout SK-MES-1 cell lines, which are notoriously hard-to-transfect.

 Available Edits using CellEDIT Engineered Cells


Knockout

Save time in the lab by boosting your research with CellEDIT. Confidently streamline your drug discovery workflow and investigate gene function with effective CRISPR knockouts.


 Find out more

Multiplex Editing

At CellEDIT, we provide you with multiplexed cell lines in 10 weeks. The efficiency and gentleness of our vector-free editing through intra-nuclear delivery, makes it an ideal system to perform multiplex gene editing in one go.


 Find out more

Schedule Now A Meeting to Discuss Your A549 Cell Line Edits

 Related Resources

Media & Downloads

On-Demand CellEDIT's CRISPR Cell Line Engineering Webinar

CellEDIT's Service Brochure

CellEDIT's Application Note n*1 - Introducing the CellEDIT Workflow

CellEDIT's Application Note n*2 - Overcoming the hard-to-transfect cell line hurdle

Open Access Publication featuring CellEDIT:  Antony, Justin S., Anabel Migenda Herranz, Tahereh Mohammadian Gol, Susanne Mailand, Paul Monnier, Jennifer Rottenberger, Alicia Roig‐Merino et al. " Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9Biotechnology Journal 19, no. 4 (2024): 2300505.

Case Study - Streamlined U2OS Cell Line Modification with the CellEDIT Service Workflow, featuring our CellEDIT Customer: Dr. Kanstantsin Siniuk.

Browse All Engineered Cell Lines